
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. demonstrated robust financial performance in the third quarter of 2025, achieving approximately 48% growth in global FFR-CT volume, which propelled revenues to $46.3 million—an impressive 41% increase year-over-year that surpassed projections. The company's gross margins improved significantly to 76.8%, reflecting an increase of 90 basis points compared to the previous year, indicating strong operational efficiency. Additionally, management noted healthy fundamentals in the core FFR-CT business, driven by increased adoption of coronary CT angiography, a growing number of accounts, and record-high utilization levels.
Bears say
HeartFlow Inc. has reported significant net losses since its inception in 2007, including losses of $95.7 million and $96.4 million in FY23 and FY24, respectively, suggesting ongoing financial instability. The company’s revenue guidance for 2025 indicates only modest growth, projecting flattish revenues for the fourth quarter compared to the third quarter, which reflects potential challenges in market penetration and adoption. Additionally, HeartFlow faces substantial reimbursement risks, as inadequate coverage or changes in payment policies from third-party payors could adversely impact the adoption of its diagnostic solutions, further complicating its path to profitability.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares